Lupin is presently trading at Rs. 827.Eighty five, up via 12.80 factors or 1.Fifty seven% from its preceding closing of Rs. 815.05 at the BSE.

The scrip opened at Rs. 804.90 and has touched a high and occasional of Rs. 828.85 and Rs. 803.00 respectively. So far 48468 shares have been traded at the counter.

The BSE institution ‘A’ stock of face fee Rs. 2 has touched a 52 week high of Rs. 986.00 on 10-Sep-2018 and a 52 week low of Rs. 723.55 on 15-May-2018.

Last one week high and coffee of the scrip stood at Rs. 889.20 and Rs. 803.00 respectively. The current marketplace cap of the organization is Rs. 37348.14 crore.

The promoters retaining inside the agency stood at 47.00%, while Institutions and Non-Institutions held 37.Sixty nine% and 15.30% respectively.

Lupin has received tentative popularity of its Apixaban Tablets, 2.5 mg and five mg from the US Food and Drug Administration (USFDA) to market a commonplace version of Bristol-Myers Squibb Company’s Eliquis Tablets, 2.Five mg and five mg.

Lupin’s Apixaban Tablets, 2.Five mg and 5mg is the generic version of Bristol-Myers Squibb Company’s Eliquis Tablets, 2.5 mg and 5 mg.

Eliquis Tablets, 2.Five mg and 5 mg had annual sales of about $6366 million inside the US (IQVIA MAT September 2018).